aTyr Pharma, Inc. (ATYR) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	190.0K	190.0K	235.0K	353.0K	10.4M
Cost of Revenue	22.5M	1.6M	—	—	1.7M
Gross Profit	(22.3M)	(1.4M)	235.0K	353.0K	8.7M
Operating Expenses
R&D Expense	47.1M	60.2M	54.4M	42.3M	42.8M
SG&A Expense	17.0M	17.6M	13.8M	13.0M	12.3M
General & Admin Expense	17.0M	17.6M	13.8M	13.0M	14.0M
Selling & Marketing Expense	—	—	—	—	(1.7M)
Other Expenses	(22.5M)	(1.6M)	—	—	—
Total Operating Expenses	41.5M	76.3M	68.1M	55.3M	55.1M
Cost and Expenses	64.0M	77.8M	68.1M	55.3M	56.8M
Operating Income (EBIT)	(63.9M)	(77.6M)	(67.9M)	(54.9M)	(46.4M)
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	3.0M	3.5M	3.9M	4.5M	1.1M
Non-Operating Income (excl Interest)	(3.0M)	(3.5M)	(3.9M)	(4.5M)	(1.1M)
EBT (Pre-Tax Income)	(60.8M)	(74.1M)	(64.0M)	(50.4M)	(45.3M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(60.8M)	(74.1M)	(64.0M)	(50.4M)	(45.3M)
Earnings from Cont. Ops	(60.8M)	(74.1M)	(64.0M)	(50.4M)	(45.3M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(60.8M)	(74.1M)	(64.0M)	(50.4M)	(45.3M)
Per Share
Basic EPS	($0.62)	($0.80)	($0.86)	($0.94)	($1.60)
Diluted EPS	($0.62)	($0.80)	($0.86)	($0.94)	($1.60)
Revenue Per Share	$0.00	$0.00	$0.00	$0.01	$0.37
Shares
Basic Shares Outstanding	98.1M	93.0M	74.3M	53.6M	28.4M
Diluted Shares Outstanding	98.1M	93.0M	74.3M	53.6M	28.4M
Profitability Metrics
EBITDA	(58.5M)	(72.6M)	(62.5M)	(47.7M)	(43.6M)
D&A	2.3M	1.6M	1.5M	2.7M	1.7M
EBIT	(60.8M)	(74.1M)	(64.0M)	(50.4M)	(45.3M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026